Prospective, randomized, single masked pilot study on the variation of choroidal blood flow analyzed through the HRA dynamic angiography in patients treated with intravitreal injection of Selective anti-VEGF (Macugen) or Pan anti-VEGF (Avastin). - ND
- Conditions
- Choroidal neovascularization in patients with age-related macular degeneration.
- Registration Number
- EUCTR2008-001600-23-IT
- Lead Sponsor
- AZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
- age beetween 50 and 80
- wet AMD with choroidal neovascularization
- absence of: any possibile systemic causes of vasculopathy, any vascular disorders of the retina and choroid, previous intravitreal drug injections, previous eye surgery.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
. previous eye surgery
. any changes at the cornea and lens level which interfere with a good visualization of fundus.
. previous intravitreal drug injections
. any possibile systemic causes of periferic vasculopathy
. hypersensitivity to the drug in study
. women in pregnancy and breast-feeding or women who have intention of having one pregnancy in the period of time of duration of the study
. prior treatment for CNV secondary to AMD in the study eye including PDT or Argon laser
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method